Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Eli Lilly study aims to bolster case for long-term Zepbound benefits

As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare on its medication, Zepbound.

We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.

Read the original at fiercehealthcare.com →

More in Health & Medicine

More from Thursday 27 August →